J. S. Dela Cruz

Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice.

S. Morrison, M. Penichet, G. Forni, 2003, Vaccine.

Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.

S. Morrison, M. Penichet, J. S. Dela Cruz, 2005, Vaccine.

Antibody-cytokine fusion proteins: innovative weapons in the war against cancer

S. Morrison, M. Penichet, T. Huang, 2004, Clinical and Experimental Medicine.

An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells

S. Morrison, M. Penichet, D. Shin, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.

S. Morrison, G. Helguera, M. Penichet, 2006, Vaccine.

Recombinant Anti-Human HER2/neu IgG3-(GM-CSF) Fusion Protein Retains Antigen Specificity and Cytokine Function and Demonstrates Antitumor Activity1

S. Morrison, M. Penichet, K. R. Trinh, 2000, The Journal of Immunology.

A murine B cell lymphoma expressing human HER2/neu undergoes spontaneous tumor regression and elicits antitumor immunity

S. Morrison, M. Penichet, J. Rosenblatt, 2001, Cancer Immunology, Immunotherapy.

Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3).

S. Morrison, M. Penichet, S. Sampogna, 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

New insights underlying the early events of dopaminergic dysfunction in Parkinson’s Disease

Jim Baun, J. S. Dela Cruz, Joshua Dela Cruz, 2023, bioRxiv.

Alpha-MSH: Could this anti-inflammatory mediator be the culprit in Parkinson’s Disease?

J. S. Dela Cruz, 2020 .

Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.

S. Morrison, A. Ribas, M. Penichet, 2006, Molecular immunology.

A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors.

S. Morrison, M. Penichet, S. Shin, 2001, Human antibodies.